GLP-1 for Weight Loss & So Much More

GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), are well-known for promoting weight loss and improving blood sugar but that's not all...

Reduced cardiovascular events independent of weight loss: The SELECT trial in Nature Medicine showed that semaglutide reduced major adverse cardiovascular events by 20% in over 17,600 people with obesity or overweight and established CVD but without diabetes.
Improved heart failure symptoms and inflammation: Semaglutide helped reduce HF-related symptoms and improved physical function and inflammatory markers regardless of weight loss.

Improved kidney health and metabolic outcomes: GLP-1 RAs have shown promise in reducing risks of renal complications and enhancing overall metabolic health.

Lowered dementia risk: A JAMA Neurology analysis of over 164,000 patients found up to 45% reduced risk of developing dementia (including Alzheimer's) in GLP-1 RA users.
Early Alzheimer’s prevention: Studies have linked semaglutide to significantly lower rates of first-time Alzheimer’s diagnoses, particularly compared to insulin.
Phase III trials underway: The EVOKE and EVOKE+ programs are testing semaglutide’s potential to reduce cognitive decline in early Alzheimer’s.
Mechanistic evidence of neuroprotection: Liraglutide has been shown to improve cognition and reduce brain shrinkage in Alzheimer’s patients in early trials.
Broader neuroprotective effects: GLP-1 RAs can reduce amyloid deposition, mitigate neuroinflammation, and protect against neuron loss in preclinical models.

Potential for reducing substance use: A phase 2 trial reported that semaglutide decreased alcohol consumption and cravings compared to placebo.
Lower risk of alcohol-related hospitalization: Real-world data showed semaglutide was associated with a lower risk of hospitalization due to alcohol use disorder and reduced incidence of alcohol intoxication and opioid overdoses.

Efficacy in fatty liver disease: GLP-1 RAs have been shown in clinical studies to improve liver inflammation, fibrosis, and steatosis in MASLD/NASH patients, performing as well as or better than traditional treatments like pioglitazone or vitamin E.

Lower risks of multiple obesity-related cancers: Large retrospective studies have linked GLP-1 use to reduced risks of cancers such as colorectal, endometrial, liver, and pancreatic when compared to other diabetes treatments.

Biological age reversal: A recent trial reported Ozempic users became, on average, 3.1 years biologically youngerover 32 weeks, with the strongest improvements in brain and inflammatory systems.
Emerging potential for aging-related conditions: Experts suggest GLP-1 RAs may help with age-related conditions such as Alzheimer’s, osteoarthritis, and certain cancers — though long-term trials are still needed.